OncoPep, Inc. Information

Through targeting multiple tumor-associated antigens with an investigational multi-peptide vaccine and a multi-tumor antigen adoptive (MTAA) T cell therapy, OncoPep’s T cell focused technologies are designed to be used on their own or in combination with other immunotherapeutics.

Website	http://oncopep.com
Revenue	$202000
Employees	4 (2 on RocketReach)
Founded	2010
Phone	+1 978-837-1129
Technologies	JavaScript , HTML , Twitter +7 more (view full list)
Industry	Biotechnology, Biotechnology Research, Drug Manufacturing & Research, Pharmaceuticals, Science and Engineering, Drug Discovery, Healthcare, Health Care, Pharmaceutical
Keywords	Cancer Immunotherapy, T Cell Therapy, Immuno Oncology, Oncology Therapeutics, Immunotherapeutic Agents, Cancer Vaccines, Clinical Stage Oncology, Targeted Cancer Therapy, Novel Cancer Therapies, Cancer Treatment, Cancer Research, Biopharmaceutical, Pharmaceutical Research
Competitors	Johnson & Johnson, Roche, Novartis, Merck & Co., Inc., Pfizer, AstraZeneca, Bristol Myers Squibb, Genentech, Amgen, Gilead Sciences +43 more (view full list)
SIC	SIC Code 87 Companies, SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 873 Companies
NAICS	NAICS Code 325414 Companies, NAICS Code 541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 54 Companies